What is the "therapeutic range" for voriconazole?

Clinical Infectious Diseases

Volumn 46, Issue 2, 2008, Pages 212-214

  Lewis, Russell E ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; TACROLIMUS; VORICONAZOLE;

ASPERGILLOSIS; BRAIN DISEASE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG WITHDRAWAL; FUNGAL VIRULENCE; HIGH RISK PATIENT; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NOTE; PATIENT MONITORING; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ANTIFUNGAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PYRIMIDINES; TRIAZOLES;

EID: 39449107233     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/524670     Document Type: Note

References (19)

1. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36:630-7.
2. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin Bfor primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.
3. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006; 45:649-63.
4. Boyd AE, Modi S, Howard SJ, Moore CB, Keevil BG, Denning DW. Adverse reactions to voriconazole. Clin Infect Dis 2004; 39:1241-4.
5. Trifilio S, Ortiz R, Pennick G, et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005; 35:509-13.
6. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109:1532-5.
7. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34:563-71.
8. Pascual A, Nieth V, Calandra T, et al. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob Agents Chemother 2007; 51:137-43.
9. Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50:1570-2.
10. Schumacher GE. Introduction to therapeutic drug monitoring. In: Schumacher GE, ed. Therapeutic drug monitoring. Norwalk, CT: Appleton and Lange, 1995.
11. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in pateints with invasive mycoses improves safety and efficacy outcomes. Clin Infect Dis 2008; 46:201-11 (in this issue).
12. Wood N, Tan K, Purkins L, et al. Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003; 56(Suppl 1):56-61.
13. Pai MP, Allen S. Voriconazole inhibition of tacrolimus metabolism. Clin Infect Dis 2003; 36:1089-91.
14. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006; 26:1730-44.
15. Wong R, Beguelin GZ, de Lima M, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2003; 122:128-34.
16. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003; 31:540-7.
17. Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 2004; 75:587-8.
18. Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34:563-71.
19. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006; 46:235-43.